DRG Epidemiology's coverage of colorectal cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of colorectal cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.

DRG Epidemiology's colorectal cancer forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with colorectal cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with colorectal cancer per year?
  • How will improvements in survival change the number of people living with a diagnosis of colorectal cancer?
  • How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for colorectal cancer?
  • Of all people diagnosed with colorectal cancer, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of colorectal cancer over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following colorectal cancer subpopulations:

  • Stage II colon cancer.
  • Stage II rectal cancer.
  • Stage III colon cancer.
  • Stage III rectal cancer.
  • Stage IV colorectal cancer wild-type BRAF and RAS, first-line (left-sided).
  • Stage IV colorectal cancer wild-type BRAF and RAS, first-line (right-sided).
  • Stage IV colorectal cancer mutant RAS, first-line.
  • Stage IV colorectal cancer mutant BRAF, first-line.
  • Stage IV colorectal cancer wild-type BRAF and RAS,second-line (left-sided).
  • Stage IV colorectal cancer wild-type BRAF and RAS,second-line (right-sided).
  • Stage IV colorectal cancer mutant RAS, second-line.
  • Stage IV colorectal cancer mutant BRAF, second-line.
  • Stage IV colorectal cancer wild-type BRAF and RAS, third-line (left-sided).
  • Stage IV colorectal cancer wild-type BRAF and RAS, third-line (right-sided).
  • Stage IV colorectal cancer mutant RAS, third-line.
  • Stage IV colorectal cancer mutant BRAF, third-line.
  • … and many more (details available on request).

Note: coverage may vary by country.

Table of contents

  • Colorectal Cancer - Epidemiology - Mature Markets

Author(s): Mudasir Khan, M.P.H.

Mudasir works as an associate epidemiologist within the epidemiology team at Decision Resources Group. He specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

Mudasir holds a masters in public health specializing in epidemiology from TISS, Mumbai.


Related Reports

Colorectal Cancer - Geographic Focus - China - Colorectal Cancer - China In-Depth - China

Colorectal cancer, a major public health concern in China, is expected to become the second-most-common form of cancer there by 2029, behind only lung cancer. The treatment of metastatic colorectal...

View Details

Colorectal Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU) Previously Treated RAS And BRAF Mutation-Positive Metastatic Colorectal Cancer

This Unmet Need report focuses on the treatment of previously treated RAS and BRAF  mutation-positive metastatic colorectal cancer. Currently, the NCCN guidelines and treatme...

View Details

Colorectal Cancer - Landscape & Forecast - Disease Landscape & Forecast

Targeted therapies and various biomarkers (e.g., RAS,

View Details

Colorectal Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)

Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are

View Details